What you need before approaching a Korean beauty OEM or ODM

The manufacturing base behind K-beauty operates at serious scale: Korean cosmetics exports reached a record $11.4 billion in 2025, shipping to 202 countries, with the United States the largest single market at $2.2 billion, according to Ministry of Food and Drug Safety figures reported by The Korea Herald. That scale is why brands come to Korean manufacturers, but industry language varies by supplier, so confirm the actual scope in writing. In broad terms, private label usually starts from an existing formula with limited changes. ODM commonly means the manufacturer contributes product development and formulation. OEM commonly means production follows a brand-owned or brand-directed specification.

The right route depends on what must be proprietary, how quickly the brand needs to launch, available development budget, testing requirements, and the volume the business can responsibly buy.

A useful RFQ lets a manufacturer decide whether the project fits its equipment, formulation library, component network, certifications, capacity, and export experience. Vague requests for a catalog and best price usually create generic answers.

The formula, bottle, pump, cap, decoration, carton, and raw materials can each have different minimums. The highest component minimum may control the project even when the factory can fill a smaller batch. Stock packaging and an existing formula usually reduce both minimums and development time; custom molds, specialty decoration, new actives, SPF, or multiple shades increase them.

Published Korean supplier examples often cite several thousand units per SKU, but there is no universal MOQ. Ask for every component minimum separately, the cost at two or three volume tiers, overage and wastage assumptions, and ownership of leftover components.

The target market must be defined before formula and label approval. An ingredient or claim acceptable in Korea may need different treatment in the United States. Under MoCRA, relevant facilities and responsible persons have defined duties, and a foreign facility may need a US agent. Product listing is not FDA approval.

Confirm in the contract who supplies each document, who owns the formula and test data, who maintains records, who handles changes, and who carries final target-market review. This is operational guidance, not legal advice.

A useful quote separates bulk, components, decoration, cartons, testing, assembly, freight terms, and optional services. A useful timeline separates brief review, sampling rounds, formula lock, component production, compatibility or stability work, bulk production, filling, quality release, and export.

Communication quality during sampling predicts the production relationship. Document decisions, approve physical standards where possible, define acceptable tolerances, and do not release bulk production before the formula, packaging, artwork, testing plan, and commercial terms are aligned.